Merck & Co. secured nonexclusive licensing rights to one of Xencor's engineering patents for a monoclonal antibody. The deal allows Merck to use the patent for an undisclosed product and gives it an option to license the same patent for future products. Xencor is entitled to an upfront payment, yearly maintenance fees and potential milestone payments and sales royalties.

Related Summaries